Skip to main content

NCCN Updates

Updated NCCN Breast Cancer Guideline Expands Treatment Recommendations for HR-Positive, HER2-Negative Disease
By Wayne Kuznar
Breast Cancer, NCCN Updates, NCCN
TOP - May 2019, Vol 12, No 2
Options for the treatment of patients with advanced hormone receptor (HR)-positive, HER2-­negative breast cancer are expanding. The updated National Comprehensive Cancer Network (NCCN) guideline (version 1.2019) for the management of invasive breast cancer is focused on HR-positive, HER2-­negative disease. Read More ›
Immunotherapy Strategies in the Updated NCCN Guideline for NSCLC Hinge on PD-L1 Testing
By Wayne Kuznar
NCCN Updates, NCCN
TOP - May 2019, Vol 12, No 2
The updated National Comprehensive Cancer Network (NCCN) guideline for non–small-cell lung cancer (NSCLC; version 3.2019) is focused on improving patient outcomes with immunotherapy. Read More ›
Updated NCCN Treatment Guideline for CML Establishes Criteria for Stopping TKI Therapy
By Wayne Kuznar
NCCN Updates, NCCN
TOP - May 2019, Vol 12, No 2
The discontinuation of a tyrosine kinase inhibitor (TKI) is considered safe and appropriate in consenting patients with chronic-phase chronic myeloid leukemia (CML) under specific circumstances and with careful molecular monitoring, according to the updated National Comprehensive Cancer Network (NCCN) management guideline for CML. Read More ›